RE:Now that we’re all AEZS shareholderslscfa wrote: How about a damn update....
"We expect enrollment in our DETECT-trial to be completed around the end of 2023"
What do you think the upfront, milestone and royalties will be for a new North American deal? They are also pursuing a potential Asian and South American deal. How likely and what terms?
The pediatric trial that was expected to be fully enrolled by the end of the year is set up to potentially prove the diagnostic as a standalone test. Currently two tests are required for diagnosis. Imagine being able to ditch the second test. How compelling is the argument AEZS is on a trajectory as a standalone.